Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing novel, small molecule therapeutic drugs to address major unmet medical needs.
Locus' proprietary computational technology rapidly and accurately identifies the biologically relevant active binding site(s) of a protein and simultaneously designs de novo novel, small molecule antagonist or agonists of the protein's activity utilizing our proprietary fragment data set.
Locus Pharmaceuticals, Inc. is backed by a group of investors including Prism Venture Partners, Cooper Hill Partners, Amerindo Investment Advisors, Delphi Ventures, ING Furman Selz, Invesco Funds, Johnson & Johnson Development Corp., Liberty Wagner Asset Management, Life Science Venture Fund, Origin Capital and W Capital Partners.
For more information on Locus Pharmaceuticals, Inc., please visit their web site at www.locuspharma.com
Locus' proprietary computational technology rapidly and accurately identifies the biologically relevant active binding site(s) of a protein and simultaneously designs de novo novel, small molecule antagonist or agonists of the protein's activity utilizing our proprietary fragment data set.
Locus Pharmaceuticals, Inc. is backed by a group of investors including Prism Venture Partners, Cooper Hill Partners, Amerindo Investment Advisors, Delphi Ventures, ING Furman Selz, Invesco Funds, Johnson & Johnson Development Corp., Liberty Wagner Asset Management, Life Science Venture Fund, Origin Capital and W Capital Partners.
For more information on Locus Pharmaceuticals, Inc., please visit their web site at www.locuspharma.com